GlassScriptPhysician profile
Michael A Rovzar
NPI 1184675688
$64,004.51
in general payments reported to CMS, 2019-2025
32 companies · $865 in 2025
The $865 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $18K · 2021: $13K · 2022: $8,645 · 2023: $186 · 2024: $470 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477 · Education: $44.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.12 |
| Education | $44.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47,785.08 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $13,462.78 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $501.44 | 2021-2025 | Tyvaso |
| Genentech USA, INC. | $404.41 | 2019-2020 | |
| Glaxosmithkline, LLC. | $309.29 | 2019-2025 | Nucala |
| Merck Sharp & Dohme LLC | $303.47 | 2023-2025 | Winrevair |
| Philips North America LLC | $160.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $135.58 | 2019-2023 | Xarelto |
| Genzyme Corporation | $127.24 | 2021-2025 | |
| Abbvie INC. | $97.96 | 2021-2025 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $74.06 | 2022-2025 | Cuvitru, Glassia |
| Electromed, INC. | $65.67 | 2025 | Smartvest |
| Grifols USA, LLC | $64.74 | 2020-2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $51.62 | 2024 | Zemaira |
| Mallinckrodt Hospital Products INC. | $49.93 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $48.37 | 2019-2020 | |
| Axsome Therapeutics, INC. | $47.13 | 2023 | Sunosi |
| Resmed Corp | $44.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $42.30 | 2019-2025 | Tezspire |
| Lilly USA, LLC | $37.25 | 2022-2025 | Zepbound |
| Intuitive Surgical, INC. | $36.65 | 2024 | |
| Shire North American Group INC | $30.62 | 2019 | |
| Sanofi Pasteur INC. | $28.35 | 2019 | |
| Allergan, INC. | $19.21 | 2019 | |
| Zoll Respicardia, INC. | $16.66 | 2025 | Remede System |
| Cmp Pharma, INC. | $16.60 | 2024 | Liqrev, Tadliq, Norliqva |
| Novo Nordisk INC | $15.73 | 2019 | |
| Almatica Pharma LLC | $15.16 | 2023 | Loreev Xr |
| Endogastric Solutions, INC | $12.91 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rovzar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.